Development of a novel continuous filtration unit for pharmaceutical process development and manufacturing

Sara Ottoboni, Chris J. Price, Christopher Steven, Elizabeth Meehan, Alastair Barton, Paul Firth, Andy Mitchell, Furqan Tahir

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The lack of a commercial laboratory, pilot and small manufacturing scale dead end continuous filtration and drying unit it is a significant gap in the development of continuous pharmaceutical manufacturing processes for new active pharmaceutical ingredients (APIs). To move small-scale pharmaceutical isolation forward from traditional batch Nutsche filtration to continuous processing a continuous filter dryer prototype unit (CFD20) was developed in collaboration with Alconbury Weston Ltd. The performance of the prototype was evaluated by comparison with manual best practice exemplified using a modified Biotage VacMaster unit to gather data and process understanding for API filtration and washing. The ultimate objective was to link the chemical and physical attributes of an API slurry with equipment and processing parameters to improve API isolation processes. Filtration performance was characterized by assessing filtrate flow rate by application of Darcy's law, the impact on product crystal size distribution and product purity were investigated using classical analytical methods. The overall performance of the 2 units was similar, showing that the prototype CFD20 can match best manual lab practice for filtration and washing while allowing continuous processing and real-time data logging. This result is encouraging and the data gathered provides further insight to inform the development of CFD20.
LanguageEnglish
Pages372-381
Number of pages10
JournalJournal of Pharmaceutical Sciences
Volume108
Issue number1
Early online date6 Sep 2018
DOIs
Publication statusPublished - 31 Jan 2019

Fingerprint

Drug products
Pharmaceutical Preparations
Washing
Processing
Practice Guidelines
Drying
Flow rate
Equipment and Supplies
Crystals

Keywords

  • continuous filtration
  • washing
  • drying
  • agglomeration
  • impurity
  • optimisation

Cite this

Ottoboni, Sara ; Price, Chris J. ; Steven, Christopher ; Meehan, Elizabeth ; Barton, Alastair ; Firth, Paul ; Mitchell, Andy ; Tahir, Furqan . / Development of a novel continuous filtration unit for pharmaceutical process development and manufacturing. In: Journal of Pharmaceutical Sciences. 2019 ; Vol. 108, No. 1. pp. 372-381.
@article{30988b5036dd40488069ba9302aa93c7,
title = "Development of a novel continuous filtration unit for pharmaceutical process development and manufacturing",
abstract = "The lack of a commercial laboratory, pilot and small manufacturing scale dead end continuous filtration and drying unit it is a significant gap in the development of continuous pharmaceutical manufacturing processes for new active pharmaceutical ingredients (APIs). To move small-scale pharmaceutical isolation forward from traditional batch Nutsche filtration to continuous processing a continuous filter dryer prototype unit (CFD20) was developed in collaboration with Alconbury Weston Ltd. The performance of the prototype was evaluated by comparison with manual best practice exemplified using a modified Biotage VacMaster unit to gather data and process understanding for API filtration and washing. The ultimate objective was to link the chemical and physical attributes of an API slurry with equipment and processing parameters to improve API isolation processes. Filtration performance was characterized by assessing filtrate flow rate by application of Darcy's law, the impact on product crystal size distribution and product purity were investigated using classical analytical methods. The overall performance of the 2 units was similar, showing that the prototype CFD20 can match best manual lab practice for filtration and washing while allowing continuous processing and real-time data logging. This result is encouraging and the data gathered provides further insight to inform the development of CFD20.",
keywords = "continuous filtration, washing, drying, agglomeration, impurity, optimisation",
author = "Sara Ottoboni and Price, {Chris J.} and Christopher Steven and Elizabeth Meehan and Alastair Barton and Paul Firth and Andy Mitchell and Furqan Tahir",
year = "2019",
month = "1",
day = "31",
doi = "10.1016/j.xphs.2018.07.005",
language = "English",
volume = "108",
pages = "372--381",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
number = "1",

}

Development of a novel continuous filtration unit for pharmaceutical process development and manufacturing. / Ottoboni, Sara; Price, Chris J.; Steven, Christopher; Meehan, Elizabeth; Barton, Alastair; Firth, Paul; Mitchell, Andy; Tahir, Furqan .

In: Journal of Pharmaceutical Sciences, Vol. 108, No. 1, 31.01.2019, p. 372-381.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of a novel continuous filtration unit for pharmaceutical process development and manufacturing

AU - Ottoboni, Sara

AU - Price, Chris J.

AU - Steven, Christopher

AU - Meehan, Elizabeth

AU - Barton, Alastair

AU - Firth, Paul

AU - Mitchell, Andy

AU - Tahir, Furqan

PY - 2019/1/31

Y1 - 2019/1/31

N2 - The lack of a commercial laboratory, pilot and small manufacturing scale dead end continuous filtration and drying unit it is a significant gap in the development of continuous pharmaceutical manufacturing processes for new active pharmaceutical ingredients (APIs). To move small-scale pharmaceutical isolation forward from traditional batch Nutsche filtration to continuous processing a continuous filter dryer prototype unit (CFD20) was developed in collaboration with Alconbury Weston Ltd. The performance of the prototype was evaluated by comparison with manual best practice exemplified using a modified Biotage VacMaster unit to gather data and process understanding for API filtration and washing. The ultimate objective was to link the chemical and physical attributes of an API slurry with equipment and processing parameters to improve API isolation processes. Filtration performance was characterized by assessing filtrate flow rate by application of Darcy's law, the impact on product crystal size distribution and product purity were investigated using classical analytical methods. The overall performance of the 2 units was similar, showing that the prototype CFD20 can match best manual lab practice for filtration and washing while allowing continuous processing and real-time data logging. This result is encouraging and the data gathered provides further insight to inform the development of CFD20.

AB - The lack of a commercial laboratory, pilot and small manufacturing scale dead end continuous filtration and drying unit it is a significant gap in the development of continuous pharmaceutical manufacturing processes for new active pharmaceutical ingredients (APIs). To move small-scale pharmaceutical isolation forward from traditional batch Nutsche filtration to continuous processing a continuous filter dryer prototype unit (CFD20) was developed in collaboration with Alconbury Weston Ltd. The performance of the prototype was evaluated by comparison with manual best practice exemplified using a modified Biotage VacMaster unit to gather data and process understanding for API filtration and washing. The ultimate objective was to link the chemical and physical attributes of an API slurry with equipment and processing parameters to improve API isolation processes. Filtration performance was characterized by assessing filtrate flow rate by application of Darcy's law, the impact on product crystal size distribution and product purity were investigated using classical analytical methods. The overall performance of the 2 units was similar, showing that the prototype CFD20 can match best manual lab practice for filtration and washing while allowing continuous processing and real-time data logging. This result is encouraging and the data gathered provides further insight to inform the development of CFD20.

KW - continuous filtration

KW - washing

KW - drying

KW - agglomeration

KW - impurity

KW - optimisation

UR - https://doi.org/10.15129/ac8c0e36-72d3-4156-9fbe-e60293e33a72

U2 - 10.1016/j.xphs.2018.07.005

DO - 10.1016/j.xphs.2018.07.005

M3 - Article

VL - 108

SP - 372

EP - 381

JO - Journal of Pharmaceutical Sciences

T2 - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 1

ER -